IM Cannabis Corp
Herzliya, Tel Aviv, Israel · Biotechnology, Cannabis, Community And Lifestyle
IM Cannabis Corp. (IMC) is a leading medical cannabis company with operations in Israel and Germany. The company provides premium cannabis products to medical patients in Israel and Germany, leveraging a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. IMC has recently exited operations in Canada to focus on achieving sustainable and pro
Key facts
- Headquarters
- Herzliya, Tel Aviv, Israel
- Employees
- Unknown
- Industries
- Biotechnology, Cannabis, Community And Lifestyle
- Status
- Public (IMCC)
- Website
- imcannabis.com
- Company page
Recent activity at IM Cannabis Corp
- : IM Cannabis to acquire 51% of Space Defense Innovations
- : IM Cannabis Corp. completed a US$225,000 convertible note financing led by an institutional investor for general corporate purposes.
- : IMC to acquire 51% of Blackaxe Technologies
- : IM Cannabis Corp. raises US$2,171,660.40 through debt financings to manage liquidity requirements.
- : IM Cannabis Corp. Appoints Asi Levi as Chief Financial Officer
- : IM Cannabis raises $4.1M in a private placement offering led by Pure Equity Ltd. to support its operations in Israel and Germany.
- : IM Cannabis
- : Im Cannabis Closes Previously Announced Acquisition Of Oranim Pharm, Jerusalem'S Leading Medical Cannabis Pharmacy
- : IM Cannabis Corp.
- : IM Cannabis Corp.
IM Cannabis Corp funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2026 | Pre-Seed | $225K |
| Jan 2026 | Debt Financing | $2.2M |
| Jul 2025 | Post-IPO Equity | $4.1M |
| Nov 2024 | Pre-Seed | $27K |
| Jul 2020 | Venture | $302K |
Leadership
- Oren Shuster, Executive Officer, Director
- Steven Mintz, Director
- Rafael Gabay, Director
- Vivian Bercovici, Director
- Marc Lustig, Director
- Oren Shuster, Executive Officer, Director
- Steven Mintz, Director
- Rafael Gabay, Director
- Vivian Bercovici, Director
- Marc Lustig, Director
- Jesse Kaplan, Director
- Marc Lustig, Director
Verified email and direct lines for IM Cannabis Corp’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
IM Cannabis Corp in the news
- IM Cannabis Regains Compliance with Nasdaq Minimum Bid Price Requirement - PR Newswire (Sep 23, 2026)
- IM Cannabis Provides Corporate Update - PR Newswire (Jul 27, 2026)
- IM Cannabis Corp. Announces First Quarter 2026 Financial Results - PR Newswire (May 13, 2026)
- IM Cannabis to Report Second Quarter 2024 Financial Results on Wednesday, August 14th at 9:00am ET - Lelezard (Aug 06, 2024)
Companies similar to IM Cannabis Corp
- Franchise Global · Biotechnology, Cannabis, Community And Lifestyle, Health Care, Medical
- Tilray Medical · Biotechnology, Cannabis, Health Care, Medical, Other
- Adastra · Biotechnology, Cannabis, Health Care, Manufacturing, Medical
- Capitan Orthopedics · Biotechnology, Health Care, Manufacturing, Medical
- Healthium Medtech · Biotechnology, Health Care, Manufacturing, Medical
About IM Cannabis Corp: questions and answers
What does IM Cannabis Corp do?
IM Cannabis Corp. (IMC) is a leading medical cannabis company with operations in Israel and Germany. The company provides premium cannabis products to medical patients in Israel and Germany, leveraging a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. IMC has recently exited operations in Canada to focus on achieving sustainable and pro
Where is IM Cannabis Corp headquartered?
IM Cannabis Corp is headquartered in Herzliya, Tel Aviv, Israel.
Has IM Cannabis Corp raised funding?
Yes. Fundz has recorded 5 funding events for IM Cannabis Corp. The most recent, Pre-Seed of $225K, was in Jul 2026.
What is the latest news on IM Cannabis Corp?
On Sep 23, 2026, IM Cannabis to acquire 51% of Space Defense Innovations
Is IM Cannabis Corp a public company?
Yes. IM Cannabis Corp is publicly traded under the ticker IMCC.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy